ALETHEIA Safety Intelligence Database
Do nanoparticle coatings (nano-hydroxyapatite, nanoclay, nano-platinum) migrate at levels of concern from consumer products?
The ALETHEIA database flags 3 nanomaterials with no_substitute_reason: "emerging_nanomaterial" plus a 4th (nano-TiO₂) as borderline. These are in consumer products (toothpaste, food packaging, cosmetics, catalytic converters). The critical question: do nanoparticles migrate from their product matrix into the body at toxicologically relevant doses? Product-bound nanoparticles may have completely different risk profiles than free nanoparticles.
This research scope addresses a fundamental gap in the safety assessment framework: the distinction between nanomaterial presence in a formulation and actual human exposure. Understanding migration mechanisms and rates is essential for updating the ALETHEIA database with exposure-informed risk classifications.
| Nanomaterial | Primary Product Use | Matrix | Migration Concern | DB Status |
|---|---|---|---|---|
| Nano-hydroxyapatite (n-HAp) | Toothpaste, dental products | Aqueous paste | Oral mucosa absorption, ingestion | no_substitute, emerging |
| Nanoclay (montmorillonite) | Food packaging barrier layers | Polymer composite | Food contact migration | no_substitute, emerging |
| Nano-platinum (Pt NPs) | Catalytic converters, cosmetics | Ceramic/cream matrix | Inhalation (exhaust), dermal | no_substitute, emerging |
| Nano-TiO₂ | Sunscreen, food additive (E171) | Cream/powder dispersion | Dermal penetration, ingestion | MODERATE risk, alternatives exist |
| Nano-SiO₂ | Food additive (E551), cosmetics | Powder/dispersion | Ingestion, inhalation | LOW-MOD, widely used |
| Nano-ZnO | Sunscreen | Cream matrix | Dermal penetration | MODERATE, alt. to chemical UV |
EU 10/2011 food contact migration tests; FDA extractables/leachables framework; ISO 10993 biocompatibility for dental/medical. How much nanoparticle actually leaves the product matrix under realistic use conditions?
Combine migration rates with product use patterns (frequency, duration, amount) to estimate daily nanoparticle intake by route (oral, dermal, inhalation). Compare to NOAEL/DNEL values where available.
Size-dependent cellular uptake, protein corona effects, lysosomal disruption, genotoxicity at nano-scale. Key question: do established bulk-material safety assessments apply, or does nano-form require separate evaluation?
Migration rate estimates (μg/cm²/day or μg/kg food) for each nanomaterial-product pair
Exposure margins for realistic consumer use scenarios
Decision framework: When does "nano in product" ≠ "nano exposure"?
DB update: Add migration_assessment object to nanomaterial compounds with matrix_bound: true/false, estimated_migration_rate, exposure_margin
Literature
2 weeks — migration data compilation, 40–80 papers
Modeling
3 weeks — diffusion modeling + Monte Carlo exposure
Hazard
1 week — hazard quotient calculations
DB Update
1 week — implement across nanomaterial entries + decision framework
Total: ~7 weeks